Monday saw the Tel Aviv Stock Exchange to be doing a moderate business. Experts affirmed that the exactly after 30 minutes of the market opening, the TA Composite Index was standing at 1,071.43, which was up .35%.
However, on the other hand, TA 100 was up by .37% which amount at 1,075.11. Experts said that the major advancements were seen by the real-estate stocks as a .72% rise was among them. The bank stocks also did a fine business, as a .45% rise was witnessed in their stocks as well.
To talk about the communication stocks then they also saw a modest rise of .39%, which stood at 530.60. Coming to technological index, it stood at 337.67, but not great advancements were shown by biomed issues, as they saw a rise of .11%, which stood at 830.63.
Though everything was moving fine, an all of a sudden decline was witnessed by the Tel Aviv Stock Exchange. All of a sudden decline made the exchange to close at lower amount. But, it has been said that the unexpected decline can be due to the rising tensions of fiscal cliff in the United States. Fiscal cliff is a tension, which has been troubling one and all in the trade.
In a Tuesday announcement, Supergiant Games studio’s founder Greg Kasavin said that the studio -- the creator of games like Bastion and Transistor -- has plans underway to launch a new action-RPG in 2017.
According to the announcement,...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
Electric vehicle manufacturer Tesla has said in a recent announcement that it is now offering free trials of its autopilot software on Model S and Model X cars. The free trials give the owners of Model S and Model X cars a chance to test...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
Electric vehicle manufacturer Tesla has said in a recent...
In an advisory published last Thursday, the US Computer...
In its annual Environmental Responsibility Report for...
Bigwig US wireless carrier AT&T's prepaid service...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).